4.6 Article

Reallocating sitting time to standing or stepping through isotemporal analysis: associations with markers of chronic low-grade inflammation

Journal

JOURNAL OF SPORTS SCIENCES
Volume 36, Issue 14, Pages 1586-1593

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/02640414.2017.1405709

Keywords

Sitting; standing; stepping; type 2 diabetes; inflammation

Categories

Funding

  1. National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care - Leicestershire, Northamptonshire and Rutland (NIHR CLAHRC - LNR)
  2. National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care - East Midlands (NIHR CLAHRC EM)
  3. NIHR Leicester Biomedical Research Centre

Ask authors/readers for more resources

Although high levels of sitting time are adversely related to health, it is unclear whether moving from sitting to standing provides a sufficient stimulus to elicit benefits upon markers of chronic low-grade inflammation in a population at high risk of type 2 diabetes (T2DM). Three hundred and seventy two participants (age=66.8 +/- 7.5years; body mass index (BMI)=31.7 +/- 5.5kg/m(2); Male=61%) were included. Sitting, standing and stepping was determined using the activPAL3(TM) device. Linear regression modelling employing an isotemporal substitution approach was used to quantify the association of theoretically substituting 60minutes of sitting per day for standing or stepping on interleukin-6 (IL-6), C-reactive protein (CRP) and leptin. Reallocating 60minutes of sitting time per day for standing was associated with a -4% (95% CI -7%, -1%) reduction in IL-6 (p=0.048). Reallocating 60minutes of sitting time for light stepping was also associated with lower IL-6 levels (-28% (-46%, -4%; p=0.025)). Substituting sitting for moderate-to-vigorous (MVPA) stepping was associated with lower CRP (-41% (-75%, -8%; p=0.032)), leptin (-24% (-34%, -12%; p0.001)) and IL-6 (-16% (-28%, 10%; p=0.036). Theoretically replacing 60minutes of sitting per day with an equal amount of either standing or stepping yields beneficial associations upon markers of chronic-low grade inflammation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Endocrinology & Metabolism

The Impact of the COVID-19 Pandemic on Ethnic Minority Groups With Diabetes

Kamlesh Khunti, Eva L. Feldman, Neda Laiteerapong, William Parker, Ash Routen, Monica Peek

Summary: Major ethnic disparities in diabetes care and outcomes existed before the COVID-19 pandemic. Diabetes is a risk factor for severe COVID-19, and the combination of ethnic disparities in diabetes care and COVID-19 outcomes may contribute to inequities in COVID-19 outcomes for people with diabetes. Ethnic minority populations have disproportionately higher rates of COVID-19 hospitalization and mortality. Limited studies suggest that minority populations with diabetes have higher rates of hospitalization and mortality compared to White populations. The reasons for these disparities are complex and involve comorbid conditions, exposure risk, and access to treatment that vary by ethnicity.

DIABETES CARE (2023)

Article Endocrinology & Metabolism

National and regional prevalence rates of diabetes in Saudi Arabia: analysis of national survey data

Bader Alqahtani, Ragab K. Elnaggar, Mohammed M. Alshehri, Kamlesh Khunti, Aqeel Alenazi

Summary: This study investigated the national and regional prevalence rates of diabetes mellitus (DM) in Saudi Arabia. The results showed a high prevalence of DM in Saudi Arabia, indicating an urgent need for public health interventions to improve early detection and lifestyle interventions for diabetes. The study emphasizes the establishment and implementation of a national diabetes prevention program to reduce the health and economic burden of diabetes.

INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES (2023)

Article Health Care Sciences & Services

Patient-rated satisfaction and improvement following hip and knee replacements: Development of prediction models

Karen O. B. Appiah, Kamlesh Khunti, Benjamin M. Kelly, Aidan Q. Innes, Zhining Liao, Michael Dymond, Robert G. Middleton, Thomas W. Wainwright, Thomas Yates, Francesco Zaccardi

Summary: This study aimed to develop risk scores of preoperative patient factors and patient-reported outcome measures (PROMs) as predictors of patient-rated satisfaction and improvement following hip and knee replacements. Analysis of prospectively collected patient data showed that preoperative PROMs were closely related to surgical outcomes. Prediction models were developed to predict dissatisfaction and lack of improvement following surgery based on easily accessible preoperative patient factors and PROMs.

JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2023)

Article Clinical Neurology

Validation of an automated sleep detection algorithm using data from multiple accelerometer brands

Tatiana Plekhanova, Alex Rowlands, Melanie J. Davies, Andrew P. Hall, Tom Yates, Charlotte L. Edwardson

Summary: The aim of this study was to evaluate the validity of an automated sleep detection algorithm applied to data from three accelerometers. The results showed that the sleep estimates obtained from the accelerometers were generally comparable to the results from polysomnography, except for wake after sleep onset.

JOURNAL OF SLEEP RESEARCH (2023)

Article Endocrinology & Metabolism

Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England

Suping Ling, Francesco Zaccardi, Eyad Issa, Melanie J. Davies, Kamlesh Khunti, Karen Brown

Summary: The aim of this study was to examine long-term trends in cancer mortality rates among individuals with type 2 diabetes, based on various demographic and risk factor subgroups. The results showed that while overall mortality rates decreased, cancer mortality rates increased in older individuals with type 2 diabetes, especially for colorectal, pancreatic, liver, and endometrial cancer. This highlights the need for tailored cancer prevention and early detection strategies to address disparities in the older population, individuals of lower socioeconomic status, and smokers.

DIABETOLOGIA (2023)

Article Endocrinology & Metabolism

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

Avraham Karasik, Stefanie Lanzinger, Elise Chia -Hui Tan, Daisuke Yabe, Dae Jung Kim, Wayne H. -H Sheu, Cheli Melzer-Cohen, Reinhard W. Holl, Kyoung Hwa Ha, Kamlesh Khunti, Francesco Zaccardi, Anuradhaa Subramanian, Krishnarajah Nirantharakumar, Thomas Nystrom, Leo Niskanen, Majken Linnemann Jensen, Fabian Hoti, Riho Klements, Anouk Deruaz-Luyet, Moe H. Kyaw, Lisette Koeneman, Dorte Vistisen, Bendix Carstensen, Sigrun Halvorsen, Gisle Langslet, Soulmaz Fazeli Farsani, Elisabetta Patorno, Julio Nunez

Summary: This non-interventional cohort study evaluated the cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to dipeptidyl peptidase-4 inhibitors. The results showed that empagliflozin was associated with a lower risk of hospitalization for heart failure, myocardial infarction, stroke, and end-stage renal disease, but a higher risk of diabetic ketoacidosis compared to dipeptidyl peptidase-4 inhibitors. The study provides further evidence of the beneficial cardiorenal effects and overall safety of empagliflozin.

DIABETES & METABOLISM (2023)

Article Endocrinology & Metabolism

Weight change and risk of obesity-related complications: A retrospective population-based cohort study of a UK primary care database

Kamlesh Khunti, Volker Schnecke, Christiane Lundegaard Haase, Nina M. Harder-Lauridsen, Naveen Rathor, Kasper Sommer, Camilla S. Morgen

Summary: This study aimed to investigate the association between weight loss/gain and the risk of developing 13 obesity-related complications (ORCs), according to baseline body mass index (BMI). The study included adults with obesity (>30 kg/m(2)) from the UK Clinical Practice Research Datalink GOLD database, and the associations were examined using Cox proportional hazard models. The results revealed four distinct patterns of association between degree of weight change, baseline BMI, and the 13 ORCs.

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

HbA1c trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study

Brenda Bongaerts, Oliver Kuss, Fabrice Bonnet, Hungta Chen, Andrew Cooper, Peter Fenici, Marilia B. Gomes, Niklas Hammar, Linong Ji, Kamlesh Khunti, Jesus Medina, Antonio Nicolucci, Marina V. Shestakova, Hirotaka Watada, Wolfgang Rathmann

Summary: This study aimed to identify different HbA1c trajectories in T2D patients starting second-line glucose-lowering therapy. Four distinct trajectories were found, with most patients achieving stable good or highly improved long-term glycaemic control. However, one-fifth of participants showed moderate or poor glycaemic control during follow-up.

DIABETES OBESITY & METABOLISM (2023)

Review Endocrinology & Metabolism

Impact of novel glucose-lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta-analysis of randomised placebo-controlled trials

Ehtasham Ahmad, Franciskos Arsenyadis, Abdullah Almaqhawi, Mary Barker, Rishi Jobanputra, Jack A. Sargeant, David R. Webb, Thomas Yates, Melanie J. Davies

Summary: This study investigated the effects of novel glucose-lowering therapies (SGLT2 inhibitors, DPP4 inhibitors, GLP-1 receptor agonists) on physical function in individuals with type 2 diabetes. The results showed that GLP-1 receptor agonists had positive effects on self-reported physical function, but further research is needed to determine the effects of SGLT2 inhibitors and DPP4 inhibitors.

DIABETIC MEDICINE (2023)

Article Multidisciplinary Sciences

An external validation of the QCOVID3 risk prediction algorithm for risk of hospitalisation and death from COVID-19: An observational, prospective cohort study of 1.66m vaccinated adults in Wales, UK

Jane Lyons, Vahe Nafilyan, Ashley Akbari, Stuart Bedston, Ewen Harrison, Andrew Hayward, Julia Hippisley-Cox, Frank Kee, Kamlesh Khunti, Shamim Rahman, Aziz Sheikh, Fatemeh Torabi, Ronan A. Lyons

Summary: The study validates the use of the QCOVID3 risk algorithm in the vaccinated population of Wales, demonstrating its applicability in assessing COVID-19 related risks and providing decision-making support.

PLOS ONE (2023)

Article Multidisciplinary Sciences

Model-based economic evaluation of the effectiveness of 'Hypos' can strike twice, a leaflet-based ambulance clinician referral intervention to prevent recurrent hypoglycaemia

Murray D. D. Smith, Colin Ridyard, Vanessa Botan, Amanda Brewster, Sally Dunmore, June James, Kamlesh Khunti, Despina Laparidou, Graham Law, Pauline Mountain, Leon Roberts, Elise Rowan, Robert Spaight, Keith Spurr, Aloysius N. N. Siriwardena

Summary: 'Hypos' can strike twice (HS2) is a leaflet-based referral intervention aimed at encouraging patients treated for hypoglycemia to engage with their healthcare providers for better medical management of diabetes, reducing the risk of recurrent hypoglycemia. An economic model comparing HS2 to standard care showed that HS2 resulted in slightly higher NHS costs (average £49.79) compared to standard care (average £40.50) in the two weeks following the initial attack. The probability of no recurrence of hypoglycemia was slightly higher under HS2 (42.4%) compared to standard care (39.4%), indicating a 7.6% reduction in relative risk. The study concludes that, in its current form, HS2 is not cost-effective compared to standard NHS care in reducing the risk of recurrent hypoglycemia within two weeks of an initial attack.

PLOS ONE (2023)

Letter Medicine, General & Internal

Response to Was the rate of Long Covid as high as 45%-a scary report with flaw

Lauren L. O'Mahoney, Ash Routen, Clare Gillies, Kamlesh Khuntia

ECLINICALMEDICINE (2023)

Article Endocrinology & Metabolism

Effect of delay in treatment intensification in people with type 2 diabetes and suboptimal glycaemia after basal insulin initiation: A real-world observational study

Sharmin Shabnam, Sophia Abner, Clare L. Gillies, Melanie J. Davies, Terry Dex, Kamlesh Khunti, David R. Webb, Francesco Zaccardi, Samuel Seidu

Summary: The study found that delayed treatment intensification increases the risk of cardiovascular disease and complications in patients with suboptimal glycaemia, especially in those under the age of 65.

DIABETES OBESITY & METABOLISM (2023)

Letter Endocrinology & Metabolism

Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal-bolus insulin in UK clinical practice

Melanie J. Davies, Amra Ciric Alibegovic, Pranav Kelkar, Uffe Christian Braae, Anders Boeck Jensen

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

Factors associated with therapeutic inertia in individuals with type 2 diabetes mellitus started on basal insulin

Sharmin Shabnam, Clare L. Gillies, Melanie J. Davies, Terry Dex, Eka Melson, Kamlesh Khunti, David R. Webb, Francesco Zaccardi, Samuel Seidu

Summary: This study aims to identify factors associated with treatment inertia in patients with type 2 diabetes mellitus who have recently started on basal insulin. The study found that older age, female gender, longer duration of T2DM, living in deprived areas, smoking, presence of comorbidities, and use of certain medications were all associated with a delayed intensification of treatment. Interventions to overcome therapeutic inertia should be implemented at both patient and healthcare professional level.

DIABETES RESEARCH AND CLINICAL PRACTICE (2023)

No Data Available